Your browser doesn't support javascript.
loading
A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis.
Najafi, Soheil; Moghadam, Nahid Beladi; Saadat, Payam; Noorbakhsh, Seyyedeh Masoomeh; Mohammadi, Anita Vali; Manouchehrinia, Ali; Hosseini, Mostafa; Matsuo, Hidenori; Mirshafiey, Abbas.
Afiliação
  • Najafi S; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Moghadam NB; Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
  • Saadat P; Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
  • Noorbakhsh SM; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammadi AV; Shiraz Branch, Islamic Azad University, Shiraz, Iran.
  • Manouchehrinia A; Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.
  • Hosseini M; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Matsuo H; National Hospital Organization, Nagasaki Kawatana Medical Center, Nagasaki, Japan.
  • Mirshafiey A; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Int J Neurosci ; 132(4): 403-412, 2022 Apr.
Article em En | MEDLINE | ID: mdl-32878514

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Ácidos Hexurônicos / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Ácidos Hexurônicos / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article